SCHEMBL747937

SCHEMBL747937

CCCCCc1ccccc1B(O)O

nearest known ligand 0.96

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 7/20 0.96
LPL P06858 6/20 0.50
TRPV1 Q8NER1 1/20 0.48
MGLL Q99685 1/20 0.48
ALOX5 P09917 1/20 0.47
PTGS2 P35354 1/20 0.47
BID P55957 3/20 0.45
MCL1 Q07820 3/20 0.45
BCL2L1 Q07817 2/20 0.45
BAK1 Q16611 2/20 0.45
KAT8 Q9H7Z6 2/20 0.45
PPARG P37231 1/20 0.45
PPARA Q07869 1/20 0.45
EP300 Q09472 1/20 0.45
KAT2A Q92830 1/20 0.45
KAT2B Q92831 1/20 0.45
KAT5 Q92993 1/20 0.45
SAE1 Q9UBE0 1/20 0.45
THRA P10827 1/20 0.44
THRB P10828 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29670235 1.00 LIPG (0.96) LIPGLPLTRPV1MGLLALOX5
Methyl Alcohol SCHEMBL28643289 0.98 LIPG (0.92) LIPGLPLTRPV1MGLLALOX5
SCHEMBL31403378 0.98 LIPG (1.00) LIPGLPLTRPV1MGLLALOX5
SCHEMBL29670093 0.98 LIPG (1.00) LIPGLPLTRPV1MGLLALOX5
SCHEMBL6153283 0.98 LIPG (1.00) LIPGLPLTRPV1MGLLALOX5
SCHEMBL31591938 0.98 LIPG (1.00) LIPGLPLTRPV1MGLLALOX5
SCHEMBL435360 0.98 LIPG (1.00) LIPGLPLTRPV1MGLLALOX5
SCHEMBL11415024 0.98 LIPG (1.00) LIPGLPLTRPV1MGLLALOX5
SCHEMBL4449189 0.98 LIPG (1.00) LIPGLPLTRPV1MGLLALOX5
SCHEMBL1128560 0.94 LIPG (0.85) LIPGLPLTRPV1MGLLALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117865773-A Preparation method of difluoromethyl aromatic compound based on palladium-catalyzed decarbonylation coupling 大连理工大学 2024-04-12 CN claimed
CN-110041174-B EBINOL axis chiral compound and synthetic method and application thereof 南方科技大学 2022-04-12 CN claimed
CN-119569754-A Thiophene pyrrole fused benzothiadiazole dichroic dye and application thereof 西安工业大学 2025-03-07 CN disclosed
CN-118388973-A Benzotriazole dichroic dye and application thereof 西安近代化学研究所 2024-07-26 CN disclosed
CN-110041174-B EBINOL axis chiral compound and synthetic method and application thereof 南方科技大学 2022-04-12 CN disclosed
CN-113149839-B Self-aligned liquid crystal medium compound and application thereof 北京八亿时空液晶科技股份有限公司 2022-02-22 CN disclosed
CN-108753312-B Liquid crystal compound, preparation method thereof, composition containing liquid crystal compound and high-frequency component containing liquid crystal medium 西安近代化学研究所 2021-07-27 CN disclosed
CN-113149839-A Self-aligned liquid crystal medium compound and application thereof 北京八亿时空液晶科技股份有限公司 2021-07-23 CN disclosed
CN-110746981-B Liquid crystal composition and application thereof 武汉轻工大学 2021-06-29 CN disclosed
CN-110760311-B Lateral methyl poly-biphenyl liquid crystal compound, liquid crystal composition and application thereof 武汉轻工大学 2021-06-29 CN disclosed
CN-108517217-B Acetylene liquid crystal compound, preparation method thereof, composition containing acetylene liquid crystal compound and high-frequency component containing acetylene liquid crystal medium 西安近代化学研究所 2020-02-14 CN disclosed
EP-1856090-A2 SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2007-11-21 EP disclosed
WO-2006086488-A2 SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2006-08-17 WO disclosed
US-20040158074-A1 Substituted biphenyl compounds for the treatment of inflammation G.D. SEARLE & CO. 2004-08-12 US disclosed
US-6677488-B2 AS AN EXAMPLE, 4-(4,5-DIFLUORO-2-(3-CHLORO-4-FLUOROPHENYL) PHENYLBENZENESULFONAMIDE; ANTIARTHRITIC AGENTS; ANTIPYRETICS; ANALGESICS; PROSTAGLANDIN INHIBITORS; SIDE EFFECT REDUCTION G.D. SEARLE & CO. 2004-01-13 US disclosed
US-20020169206-A1 Substituted biphenyl compounds for the treatment of inflammation G.D. SEARLE & CO. (US) 2002-11-14 US disclosed
EP-0794942-B1 SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2000-05-31 EP disclosed
US-5739166-A ALKYLSULFONYL OR AMINOSULFONYL SUBSTITUTED AROMATIC COMPOUNDS AS NON-STEROIDAL ANTIINFLAMMATORY AGENT G.D. SEARLE & CO. (US) 1998-04-14 US disclosed
EP-0794942-A1 SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1997-09-17 EP disclosed
WO-1996016934-A1 SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-06-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169206-A1 Substituted biphenyl compounds for the treatment of inflammation AHR, ARNT, GPBAR1 LIPG 628/4885LPL 501/4885TRPV1 917/4885
US-20040158074-A1 Substituted biphenyl compounds for the treatment of inflammation AHR, ARNT, GPBAR1 LIPG 628/4885LPL 501/4885TRPV1 917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.